Atrial Flutter Treatment Guidelines

Initial Management

The American Heart Association recommends immediate synchronized cardioversion for patients with atrial flutter who are hemodynamically unstable 1
Cardioversion for atrial flutter can be successful at lower energy levels than for atrial fibrillation, according to the American College of Cardiology 1
Appropriate anticoagulation considerations should be addressed prior to cardioversion when possible, as suggested by the American Heart Association 2

The American College of Cardiology recommends intravenous diltiazem as the preferred calcium channel blocker due to its safety and efficacy profile 1
Esmolol is generally the preferred intravenous beta blocker for acute rate control because of its rapid onset, as stated by the American Heart Association 3
Important medication considerations: avoid diltiazem and verapamil in patients with advanced heart failure, heart block, or sinus node dysfunction without pacemaker therapy, according to the American College of Cardiology 3

Elective synchronized cardioversion is indicated in stable patients when pursuing rhythm control, as recommended by the American Heart Association 1
Pharmacological cardioversion options: oral dofetilide or intravenous ibutilide (effective in approximately 60% of cases), according to the American College of Cardiology 4
Catheter ablation of the CTI is the most effective long-term rhythm control strategy, as stated by the American Heart Association 4

Antithrombotic therapy in patients with atrial flutter should follow the same protocols as for atrial fibrillation, according to the American College of Cardiology 4
Risk of stroke in atrial flutter is significant, with reported rates of 3% annually, as stated by the American Heart Association 2

Rate control can be more difficult to achieve in atrial flutter than in atrial fibrillation due to less concealed AV nodal conduction, as noted by the American College of Cardiology 1
Atrial flutter and atrial fibrillation frequently coexist—22-50% of patients develop atrial fibrillation within 14-30 months after CTI ablation, according to the American Heart Association 4
Risk factors for developing atrial fibrillation after atrial flutter ablation include prior atrial fibrillation, depressed left ventricular function, structural heart disease, and increased left atrial size, as stated by the American College of Cardiology 4

When the duration of atrial flutter is >48 hours or uncertain, rate control should be optimized first and patients should receive therapeutic anticoagulation for 3 weeks before and 4 weeks after planned cardioversion, as recommended by the American Heart Association 5